Supplementary Materials

Supplementary Material for:

Leukotriene B4 antagonism ameliorates experimental lymphedema

Wen Tian, Stanley G. Rockson,* Xinguo Jiang, Jeanna Kim, Adrian Begaye, Eric M. Shuffle, Allen B. Tu, Matthew Cribb, Zhanna Nepiyushchikh, Abdullah H. Feroze, Roham T. Zamanian, Gundeep S. Dhillon, Norbert F. Voelkel, Marc Peters-Golden, Jan Kitajewski, J. Brandon Dixon, Mark R. Nicolls*

*Corresponding author. Email: rockson{at} (S.G.R.); mnicolls{at} (M.R.N.)

Published 10 May 2017, Sci. Transl. Med. 9, eaal3920 (2017)
DOI: 10.1126/scitranslmed.aal3920

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Mouse tail model of acquired lymphedema.
  • Fig. S2. Analysis of mouse tail edema and LTB4 and BLT1 expression after LTB4 antagonism started on postoperative day 3.
  • Fig. S3. Bestatin treatment reduces inflammation.
  • Fig. S4. Macrophage depletion does not resolve mouse tail lymphedema.
  • Fig. S5. Bestatin treatment reduces microvascular permeability in mouse tail lymphedema.
  • Fig. S6. LTB4 inhibits in vivo and in vitro HLEC lymphangiogenesis.
  • Fig. S7. LTB4 (400 nM) damages HLEC junctions and reduces connexin mRNA transcript.
  • Fig. S8. 5-LO expression in neutrophils and macrophages is increased in human lymphedema.
  • Fig. S9. Increased LTB4 and decreased PGE2 signaling in mouse tail lymphedema.
  • Fig. S10. LTB4 antagonism before initial lymphangiogenesis period is not therapeutic.
  • Fig. S11. LTB4 exerts concentration-dependent effects on HLEC VEGFR2 signaling.
  • Fig. S12. Overexpressing 5-LO interferences lymphatic drainage and promotes microvascular leakage in mouse tail.
  • Fig. S13. LTB4 (200 nM) inhibits Notch signaling in HLECs.
  • Fig. S14. Confirmation of the generation of Prox1-specific, Notch1-deficient (Notch1LECKO) mice.
  • Fig. S15. Bestatin does not rescue Notch signaling or limit lymphatic dilation in Notch1LECKO mice.
  • Fig. S16. Effects of bestatin on inflammation and microvascular permeability in Notch1LECKO mice.
  • Fig. S17. Bestatin does not rescue tail lymphedema in mice treated with DAPT.
  • Table S1. Demographics of healthy controls and lymphedema patients—LTB4 and PGE2 analysis.
  • Table S2. Summary of lymphangiogenesis and angiogenesis microarray results.
  • Legends for movies S1 to S3

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). Primary data.
  • Movie S1 (.mp4 format). NIR imaging of collecting lymphatics in the healthy control mouse.
  • Movie S2 (.mp4 format). NIR imaging of collecting lymphatics in the bestatin-treated mouse after lymphatic ablation surgery.
  • Movie S3 (.mp4 format). NIR imaging of collecting lymphatics in the saline-treated mouse after lymphatic ablation surgery.